Clinical Trial Update: First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH [Phase 1, Phase 2]

View source ↗

Summary

First-in-human study of BCX9930 in healthy volunteers and PNH patients completed, reporting Phase 1/2 results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• BCX9930 (Factor D inhibitor)

Snippet

Sponsor: BioCryst Pharmaceuticals | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 1, Phase 2 | Status: COMPLETED